Enzolytics Inc (ENZC)

[falon]

ENZC have already been through CLINICAL TRIALS!!!

We follow the SCIENCE!!!

CLINICAL TRIALS already PROVED ITV-1 is EFFECTIVE against HIV!!!

ENZC CLAIMS is based on SCIENTIFIC DATA


One Company technology, invented by Harry Zhabilov, the CSO of the Company, includes a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. This therapeutic, known as ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union. HIV patients tested in these trials showed the following beneficial outcomes:

1. Improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK, and of the index CD4/CD8.

2. Decrease in the viral load.

3. Demonstrated beneficial effect on opportunistic infections.

4. Demonstrated very good compatibility with all of the other modern antiretroviral drugs.

5. Demonstrated very good tolerance in all patients and complete absence of side effects.

You Said:

It has nothing to do with whether or not these things can make money, it has to do with validation of these erroneous claims. You cant prove that it will happen any more than they can ethically say that they can produce a drug with the success rate that they claim from their computer generated data.

FINAL REPORT


https://www.researchgate.net/publication/320011459_ITV-1_Irreversible_Pepsin_Fraction_Clinical_Data_from_Bulgarian_Phase_III_Clinical_Trial

SINGLE-CENTER PARALLEL-GROUP TRIAL WITH AN OPEN-LABEL AND TWO TREATMENT ARMS, TO EVALUATE THE EFFICACY AND SAFETY OF 16-WEEKS OF INJECTION ADMINISTRATION OF ITV-1-IMMUNH IN COMBINATION WITH AN ANTIRETROVIRAL THERAPY IN HIV-POSITIVE PATIENTS WITH ADVANCED AIDS”

Dated: 07 August, 2014

Summarizing the results from the present clinical trial, we can draw the following conclusions:

1. The application of the product ITV-1-lmmunH shows good efficacy in patients with HIV-1 infection in its various stages - in 21 of them (68%) from the main group we note an increase in CD4 + T- lymphocytes; in 16 of them the increase is accompanied by an increase in the index CD4/CD8 and CD4%, which corresponds to a reduction in the immune activation. The increase in these parameters is statistically significant compared to the control group. The
absolute number and the relative share of C08 + T lymphocytes is decreasing, too.
2. We observe a very good virological effect – the viral load in 80.5% of the patients is below the threshold of detection (however, we have no comparison to the control group).
3. The application of the product ITV-1-lmmunH is well tolerated - only one patient manifested allergic dermal response. With regard to none of them we found variations in the hematological and biochemical parameters, neither did we establish clinically significant abnormal vital signs.